BACKGROUND: The chemokine CCL25, and its receptor CCR9, constitute a unique chemokine/receptor pair, which regulates trafficking of T lymphocytes to the small intestine under physiological conditions and is an attractive target for small bowel Crohn's disease drug development. We have previously shown that CCL25/CCR9 interactions regulate the recovery from acute dextran sulfate sodium-induced colonic inflammation. In this study, we explored whether these interactions also regulate chronic colitis development in 2 independent murine models of experimental colitis. METHODS: Histological flow cytometry and qPCR analyses were performed to evaluate the role of CL25 and CCR9 in chronic colonic inflammation induced by serial exposures to dextran sulfate sodium salts or by adoptive transfer of CD45RB(hi) CD4(+) T cell into lymphopenic mice devoid of CCL25/CCR9 interactions. RESULTS: Chronic dextran sulfate sodium exposure results in exacerbated colitis in mice deficient for either CCR9 or CCL25 when compared with wild-type control mice. Although CCR9-deficient T cells traffic to the colon and induce severe colitis similar to wild-type T cells in the CD45RB transfer model, naive wild-type T cells induce more severe disease in recipient animals devoid of CCL25 expression. CONCLUSIONS: CCL25/CCR9 interactions are required for modulating protection against large intestinal inflammation in 2 models of chronic colitis. These data may have implications for the potential effects of disrupting CCL25/CCR9 interactions in humans in the setting of intestinal disorders including inflammatory bowel disease.
BACKGROUND: The chemokine CCL25, and its receptor CCR9, constitute a unique chemokine/receptor pair, which regulates trafficking of T lymphocytes to the small intestine under physiological conditions and is an attractive target for small bowel Crohn's disease drug development. We have previously shown that CCL25/CCR9 interactions regulate the recovery from acute dextran sulfate sodium-induced colonic inflammation. In this study, we explored whether these interactions also regulate chronic colitis development in 2 independent murine models of experimental colitis. METHODS: Histological flow cytometry and qPCR analyses were performed to evaluate the role of CL25 and CCR9 in chronic colonic inflammation induced by serial exposures to dextran sulfate sodium salts or by adoptive transfer of CD45RB(hi) CD4(+) T cell into lymphopenicmice devoid of CCL25/CCR9 interactions. RESULTS: Chronic dextran sulfate sodium exposure results in exacerbated colitis in mice deficient for either CCR9 or CCL25 when compared with wild-type control mice. Although CCR9-deficient T cells traffic to the colon and induce severe colitis similar to wild-type T cells in the CD45RB transfer model, naive wild-type T cells induce more severe disease in recipient animals devoid of CCL25 expression. CONCLUSIONS:CCL25/CCR9 interactions are required for modulating protection against large intestinal inflammation in 2 models of chronic colitis. These data may have implications for the potential effects of disrupting CCL25/CCR9 interactions in humans in the setting of intestinal disorders including inflammatory bowel disease.
Authors: Hanna Stenstad; Anna Ericsson; Bengt Johansson-Lindbom; Marcus Svensson; Jan Marsal; Matthias Mack; Dominic Picarella; Dulce Soler; Gabriel Marquez; Mike Briskin; William W Agace Journal: Blood Date: 2006-01-03 Impact factor: 22.113
Authors: K A Papadakis; J Prehn; V Nelson; L Cheng; S W Binder; P D Ponath; D P Andrew; S R Targan Journal: J Immunol Date: 2000-11-01 Impact factor: 5.422
Authors: A P Vicari; D J Figueroa; J A Hedrick; J S Foster; K P Singh; S Menon; N G Copeland; D J Gilbert; N A Jenkins; K B Bacon; A Zlotnik Journal: Immunity Date: 1997-08 Impact factor: 31.745
Authors: S E Erdman; V P Rao; T Poutahidis; A B Rogers; C L Taylor; E A Jackson; Z Ge; C W Lee; D B Schauer; G N Wogan; S R Tannenbaum; J G Fox Journal: Proc Natl Acad Sci U S A Date: 2009-01-21 Impact factor: 11.205
Authors: Satish Keshav; Tomáš Vaňásek; Yaron Niv; Robert Petryka; Stephanie Howaldt; Mauro Bafutto; István Rácz; David Hetzel; Ole Haagen Nielsen; Séverine Vermeire; Walter Reinisch; Per Karlén; Stefan Schreiber; Thomas J Schall; Pirow Bekker Journal: PLoS One Date: 2013-03-20 Impact factor: 3.240
Authors: Sangwon V Kim; Wenkai V Xiang; Changsoo Kwak; Yi Yang; Xiyao W Lin; Mitsuhiko Ota; Umut Sarpel; Daniel B Rifkin; Ruliang Xu; Dan R Littman Journal: Science Date: 2013-05-09 Impact factor: 47.728
Authors: Palak J Trivedi; Tony Bruns; Stephen Ward; Martina Mai; Carsten Schmidt; Gideon M Hirschfield; Chris J Weston; David H Adams Journal: J Autoimmun Date: 2016-02-09 Impact factor: 7.094
Authors: C López-Pacheco; G Soldevila; G Du Pont; R Hernández-Pando; E A García-Zepeda Journal: Mediators Inflamm Date: 2016-10-04 Impact factor: 4.711
Authors: Claire Galand; Juan Manuel Leyva-Castillo; Juhan Yoon; Alex Han; Margaret S Lee; Andrew N J McKenzie; Michael Stassen; Michiko K Oyoshi; Fred D Finkelman; Raif S Geha Journal: J Allergy Clin Immunol Date: 2016-06-02 Impact factor: 10.793
Authors: Heather L Evans-Marin; Anthony T Cao; Suxia Yao; Feidi Chen; Chong He; Han Liu; Wei Wu; Maria G Gonzalez; Sara M Dann; Yingzi Cong Journal: PLoS One Date: 2015-07-31 Impact factor: 3.240
Authors: Christopher R Heier; Alyson A Fiorillo; Ellen Chaisson; Heather Gordish-Dressman; Yetrib Hathout; Jesse M Damsker; Eric P Hoffman; Laurie S Conklin Journal: Clin Transl Gastroenterol Date: 2016-09-15 Impact factor: 4.488